亦诺微医药递表港交所 花旗中金联席保荐
2026-07-16 11:07:30
据明报报道，专注于临床需求导向的未盈利生物科技公司亦诺微医药（Immvira Bioscience）今日根据《上市规则》第18A章向港交所递交上市申请，花旗及中金（3908）为联席保荐人。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
TopNotchYJ：BTC转向长期吸筹Next article：
QCP称油价利率与加密融资分化
